The brief discusses the congressional intent and the proper application public disclosure bar and the importance of outside relators in reigning in healthcare costs related to pharmaceutical frauds, while rebutting the Chamber of Commerce and PhRMA’s arguments that there are too many qui tam actions filed and the public disclosure bar should be applied broadly to limit them, and that declined cases are meritless. 

Download the Amicus Brief here.